LAS VEGAS, July 16, 2026 /PRNewswire/ -- The treatment landscape for C3G has historically depended on the off-label use of multiple prescription therapies, underscoring the substantial unmet need for ...
An interferon-stimulated genes signature including IFI27 and OAS1, together with complement levels, may reflect the immune state of patients with SLE and identify active disease. An automated ...
Although the vaccine cavalry is finally coming over the hill, the need for better drugs to treat those with COVID-19 remains. Many drugs are being tested in patients at different stages of the disease ...
Emerging therapies targeting novel mechanisms such as dual complement inhibitors (C5 and Factor H (KP104), MASP-3 inhibitors (Zaltenibart), RNA interference (RNAi) therapeutics targeting complement C3 ...
Emerging therapies targeting novel mechanisms such as dual complement inhibitors (C5 and Factor H (KP104), MASP-3 inhibitors (Zaltenibart), RNA interference (RNAi) therapeutics targeting complement C3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results